These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3263243)

  • 1. Inhibition of complement activation by high-dose corticosteroids in total hip arthroplasty.
    Gammer W; Bengtson A; Heideman M
    Clin Orthop Relat Res; 1988 Nov; (236):205-9. PubMed ID: 3263243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of anaphylatoxin formation by high-dose corticosteroids in total hip arthroplasty.
    Gammer W; Bengtson A; Heideman M
    Prog Clin Biol Res; 1989; 308():879-83. PubMed ID: 2789402
    [No Abstract]   [Full Text] [Related]  

  • 3. [Atopic dermatitis. II. The status of complement proteins and the pathogenetic role of anaphylatoxins C4a, C3a and C5a].
    Sergeev IuV; Reznikov IuP; Lobanova EV; Pimenova NS
    Vestn Dermatol Venerol; 1989; (4):4-7. PubMed ID: 2788339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaphylatoxin levels in human aqueous humor.
    Mondino BJ; Sumner H
    Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1288-92. PubMed ID: 3488296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaphylatoxin release in association with methylmethacrylate fixation of hip prostheses.
    Bengtson A; Larsson M; Gammer W; Heideman M
    J Bone Joint Surg Am; 1987 Jan; 69(1):46-9. PubMed ID: 3805070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the anaphylatoxin inactivator and chemotactic factor inactivator activities during cardiopulmonary bypass.
    Kreutzer DL; McCormick JR; Despins A; Moore M; Rousou JH; Dobbs W; Engleman RN
    J Exp Pathol; 1984; 1(3):183-7. PubMed ID: 6336305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins.
    Chenoweth DE; Cooper SW; Hugli TE; Stewart RW; Blackstone EH; Kirklin JW
    N Engl J Med; 1981 Feb; 304(9):497-503. PubMed ID: 7453783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary injury induced by C3a and C5a anaphylatoxins.
    Stimler NP; Hugli TE; Bloor CM
    Am J Pathol; 1980 Aug; 100(2):327-48. PubMed ID: 6967702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement activation and anaphylatoxin (C3a and C5a) formation in preeclampsia and by amniotic fluid.
    Haeger M; Bengtson A; Karlsson K; Heideman M
    Obstet Gynecol; 1989 Apr; 73(4):551-6. PubMed ID: 2784554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory mediators in patients with ischemic limbs.
    Bengtson A; Holmberg P; Heideman M
    Prog Clin Biol Res; 1987; 236A():11-8. PubMed ID: 3497404
    [No Abstract]   [Full Text] [Related]  

  • 11. Anaphylatoxin levels in human vitreous humor.
    Mondino BJ; Sidikaro Y; Sumner H
    Invest Ophthalmol Vis Sci; 1988 Jul; 29(7):1195-8. PubMed ID: 3262096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of human C3a, C4a, and C5a anaphylatoxins by protein A of Staphylococcus aureus and immobilized protein A reagents used in serotherapy of cancer.
    Langone JJ; Das C; Bennett D; Terman DS
    J Immunol; 1984 Aug; 133(2):1057-63. PubMed ID: 6610702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a).
    Schifferli JA; Steiger G; Paccaud JP
    Clin Exp Immunol; 1986 May; 64(2):407-14. PubMed ID: 3488858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative modeling of proteins in the complement pathway.
    Greer J; Mollison KW; Carter GW; Zuiderweg ER
    Prog Clin Biol Res; 1989; 289():385-97. PubMed ID: 2786214
    [No Abstract]   [Full Text] [Related]  

  • 15. Complement and dengue haemorrhagic fever/shock syndrome.
    Malasit P
    Southeast Asian J Trop Med Public Health; 1987 Sep; 18(3):316-20. PubMed ID: 3501613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaphylatoxins inhibit C2 production.
    Lappin D; Damerau B; Whaley K
    Clin Exp Immunol; 1983 Nov; 54(2):455-60. PubMed ID: 6317240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis.
    Niskanen RO; Korkala OL
    Acta Orthop; 2005 Dec; 76(6):829-32. PubMed ID: 16470437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement activation produced by biomaterials.
    Chenoweth DE
    Artif Organs; 1988 Dec; 12(6):508-10. PubMed ID: 3265053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ischaemic leg as a source of complement activation.
    Bengtson A; Holmberg P; Heideman M
    Br J Surg; 1987 Aug; 74(8):697-700. PubMed ID: 3498527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement and anaphylatoxin responses to cross-clamping of the aorta. Studies during general anaesthesia with or without extradural blockade.
    Bengtson A; Lannsjö W; Heideman M
    Br J Anaesth; 1987 Sep; 59(9):1093-7. PubMed ID: 3499158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.